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Advances Illuminated by Imaging*James A. Goldstein, MDSEE PAGE 1130T he past 4 decades have witnessed amazingand once unimaginable advances in the man-agement of cardiovascular diseases. How-
ever, the trajectory of progress has rarely been
linear and the path often strewn with obstacles. Expe-
rience has taught us that innovations often beget un-
foreseen problems. This lesson was quickly learned
from the introduction of surgically implantable pros-
thetic valves, in which optimism that valve replace-
ment had “solved” the scourge of stenosis and
regurgitation was tempered by realization that these
devices had created the unexpected chronic condi-
tion of “prosthetic valve disease,” characterized by
the maladies of valve thrombosis, complications of
anticoagulant agents, prosthetic endocarditis, and
patient-valve mismatch (1).
The saga of percutaneous management of coronary
artery disease (CAD) is similarly punctuated by
thrilling advances subdued by unanticipated conse-
quences. Bare metal stents (BMS) were introduced
with the expectation that they would obviate the
challenges of acute closure and restenosis that
limited balloon angioplasty. The hope that BMS might
be a “free lunch” was dashed when the “bill came
due” with recognition of their attendant complica-
tions of acute stent thrombosis (ST) and later in-stent
restenosis (ISR). These limitations gave birth to drug-
eluting stents, which although a major advance,
unfortunately proved to be less than a “pure cure,”
reducing but not eliminating ST and ISR, and
compelling the burdens of prolonged dual anti-
platelet therapy (DAPT).
Thus, metallic coronary stents constitute both a
remedy and a “disease.” However, as emphasized in*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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owns equity in Infraredx.the paper by Garcia-Garcia et al. (2) in this issue of
iJACC, the advent of bioresorbable coronary stress
may represent a paradigm shift that cuts the “Gordian
knot” that inextricably linked stents to metallic-
induced complications and encumbrances. This
elegant treatise was written by a premier group of
researchers expert in imaging assessment and inter-
ventional management of CAD and pioneers in coro-
nary device therapeutics. The format of the paper
synergistically melds 2 ﬁelds of innovation, coronary
imaging and therapeutics, highlighting the nexus
through which advances in direct coronary imaging
have informed and facilitated the development of
these novel bioresorbable vascular scaffolds (BRS).This piece comprehensively reviews the distinct
designs and beneﬁts of the BRS, focusing on the
compelling clinical advantages these devices may
offer. As eloquently emphasized, BRS represent a
“revolutionary change in applying local coronary
therapies” and offer the “unique ability to provide a
temporary scaffold that is necessary to maintain the
patency of the vessel after intervention, releasing
antiproliferative drugs and then they gradually
degrade, liberating the vessel from its cage, permit-
ting the restoration of vascular physiology and
integrity.” The paper reviews data to support the
novel and provocative concept that implantation of
BRS rather than permanent metallic cages may facil-
itate restoration of “vessel vasomotor tone, adaptive
shear stress, late luminal enlargement, and late
expansive remodeling.” Of great practical impact,
they emphasize that “advantages over metallic stents
include reduced thrombotic propensity, which will
hopefully mitigate the burdens of DAPT” (2).
An enlightening component of the present paper is
the contrapuntal weaving of the importance of
advances in direct coronary imaging to development
of coronary therapeutics. The paper will be valued as
a scholarly primer on “methods and parameters”
relevant to assessing CAD and stents in general, and
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1150speciﬁcally as pertains to BRS. Direct coronary imag-
ing modalities, from light to sound based, are
considered in great detail, with emphasis on how the
morphological and functional parameters they pro-
vide not only delineate CAD pathophysiology but
importantly the manner in which they illuminate the
mechanisms, strengths, and limitations of novel cor-
onary interventions. Speciﬁcally, they illustrate how
advanced coronary imaging is essential to apprecia-
tion of the assessment of BRS with respect to how
“design, degradation rate, loss of mechanical prop-
erties, coating, and drug deliverability may affect its
safety and efﬁcacy.”
This paper raises 2 additional potential advantages
of BRS that may have enormous clinical impact.
Explicitly, the researchers emphasize the superior
radiological “transparency” of BRS, which may facil-
itate evaluation of suspected recurrent ischemia
(particularly when and if advances fulﬁll the promise
of reliable computed tomography angiography [CTA]–
myocardial perfusion assessment). BRS “imagability”
by CTA may also impart an attractive advantage for
pharmacological and device trials that require serial
coronary imaging. Implicitly, another potential BRS
application may be as the device basis for therapeutic
strategies designed to prevent acute myocardial
infarction and sudden coronary death by pre-emptivestenting of non–ﬂow-limiting but “vulnerable” pla-
ques (3). BRS properties and promises of healing with
a resultant repaved “golden tube,” enhanced vessel
segment elasticity and vasomotion, and the potential
of lesser ISR and stent failure may have implications
for this “holy grail” for heart attack. Clearly, future
studies will be necessary to determine if such promise
can be fulﬁlled.
The researchers should be congratulated for this
erudite treatise that ignites excitement for the bene-
ﬁts of BRS and serves as an “instructional manual” for
the toolbox for assessing these novel coronary de-
vices. The material is authoritative, insightful, and
practical. The paper highlights how innovations in
therapeutic coronary devices are intimately linked to
advances in direct coronary imaging: Without the
latter, the development of and beneﬁts derived by the
former would be less robust. This paper will serve as
a basis of reference for clinicians in the care of
their patients and for clinical researchers designing
approaches to studies of future coronary devices.
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